Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis

British Journal of Dermatology

Volumn 162, Issue 4, 2010, Pages 751-758

  Jinnin, M ^a   Makino, T ^a   Kajihara, I ^a   Honda, N ^a   Makino, K ^a   Ogata, A ^a   Ihn, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Collagen disease; Fibrosis

Indexed keywords

MESSENGER RNA; RNA; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FIBROSIS; MALE; MICROANGIOPATHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VITAL CAPACITY; BLOOD; CASE CONTROL STUDY; COLLAGEN DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; STATISTICS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COLLAGEN DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RAYNAUD DISEASE; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 77949810710     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09567.x     Document Type: Article

References (33)

1. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989 1 : 479 484.
2. Mauch C, Krieg T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990 16 : 93 107.
3. Mulligan-Kehoe MJ, Simons M. Vascular disease in scleroderma: angiogenesis and vascular repair. Rheum Dis Clin North Am 2008 34 : 73 9.
4. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005 94 : 209 231.
5. Barleon B, Siemeister G, Martiny-Baron G et al. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997 57 : 5451 5455.
6. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006 312 : 549 560.
7. Brekken RA, Overholser JP, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000 60 : 5117 5124.
8. Skobe M, Rockwell P, Goldstein N et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997 3 : 1222 1227.
9. Distler O, Distler JHW, Scheid A et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004 95 : 109 116.
10. Davies C, Jeziorska M, Freemont A et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006 37 : 190 197.
11. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993 90 : 10705 10709.
12. Kendall RL, Wang G, DiSalvo J et al. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem Biophys Res Commun 1994 201 : 326 330.
13. Wallner W, Sengenberger R, Strick R et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007 112 : 51 7.
14. Schlembach D, Wallner W, Sengenberger R et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007 29 : 407 413.
15. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15 : 202 206.
16. Ihn H, Sato S, Fujimoto M et al. Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis. Clin Exp Immunol 1996 37 : 1188 1192.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980 23 : 581 590.
18. Ihn H, Sato S, Tamaki T et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992 284 : 391 395.
19. Shibata E, Rajakumar A, Powers RW et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005 90 : 4895 4903.
20. Hudson M, Thombs B, Baron M et al. Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum 2009 61 : 274 278.
21. Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003 163 : 571 581.
22. Wan MC, Moore T, Hollis S et al. Ankle brachial pressure index in systemic sclerosis: influence of disease subtype and anticentromere antibody. Rheumatology 2001 40 : 1102 1105.
23. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975 4 : 351 368.
24. Czömpöly T, Simon D, Czirják L, Németh P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009 8 : 692 696.
25. Gomer RH. Circulating progenitor cells and scleroderma. Curr Rheumatol Rep 2008 10 : 183 188.
26. Kuwana M, Okazaki Y, Yasuoka H et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004 364 : 603 610.
27. Del Papa N, Colombo G, Fracchiolla N et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004 50 : 1296 1304.
28. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004 8 : 498 508.
29. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 275 : 964 967.
30. Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999 5 : 434 438.
31. Avouac J, Juin F, Wipff J et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008 67 : 1455 1460.
32. Choi JJ, Min DJ, Cho ML et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003 30 : 1529 1533.
33. Murasawa S, Asahara T. Endothelial progenitor cells for vasculogenesis. Physiology (Bethesda) 2005 20 : 36 42.